Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM4072
- Development stage
- Unknown
- Lead developer
- Rhythm Pharmaceuticals
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
CAM4072 is a once-weekly, long-acting subcutaneous depot formulation of setmelanotide, a melanocortin-4 receptor (MC4R) agonist. Developed by Rhythm Pharmaceuticals in partnership with Camurus, it utilizes Camurus' proprietary FluidCrystal® technology to provide sustained release of the peptide. Setmelanotide targets the MC4R pathway, which is critical for regulating energy expenditure and appetite. CAM4072 is being developed for the treatment of rare genetic obesity disorders, including Bardet-Biedl syndrome and Alström syndrome, aiming to improve patient compliance and adherence compared to the daily subcutaneous formulation (Imcivree).
- Other names
- setmelanotide weekly depotweekly setmelanotide
02
Targets
Beyond the preview
Go deeper on CAM4072.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAM4072.